PerDUCing results
This article was originally published in The Gray Sheet
Executive Summary
Comedicus, Inc. will submit data to FDA from a 20-patient study of the PerDUCER by year-end to secure 510(k) clearance for the pericardial access device. The Columbia Heights, Minnesota company plans to develop electrophysiology mapping and ablation, drug delivery and MRI applications capitalizing on the PerDUCER's potential ability to provide minimally invasive intrapericardial guidewire access to the heart's external walls. However, the privately-held firm anticipates being acquired before those indications are developed...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.